A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants

Inclusion Criteria:

• 18 to 50 years of age inclusive, at the time of signing the informed consent

• Are overtly healthy as determined by medical evaluation, including medical history,physical exam, laboratory tests, and cardiac/blood pressure monitoring

Exclusion Criteria:

• Female participants who are pregnant, nursing, or lactating

• History or presence of clinically significant allergy or allergy to band aids,adhesive dressing, electrocardiogram (ECG) patches, or medical tape

• History or presence of gastrointestinal (including prior bariatric bypass surgery),hepatic or renal disease, or any other condition that may interfere with absorption,distribution, metabolism, or excretion of drugs

• Presence of renal impairment or calculated creatinine clearance < 80 mL/min

• Triplicate 12-lead ECG demonstrating a mean QTcF > 450 msec for males and > 470 msecfor females or any other clinically significant ECG abnormality per investigatorassessment at Screening or Day -1

• Presence or history of significant cardiovascular disease including but not limitedto: myocardial infarction, uncontrolled hypertension, systolic blood pressure > 140mmHg or diastolic blood pressure > 90 mmHg (at Screening or Day -1), anginapectoris, clinically significant arrhythmias, clinically significant valvular heartdisease, history of any revascularization procedures or second or third-degree heartblock with/without a pacemaker, heart failure, or family history of Torsades dePointes

• Laboratory value(s) outside the laboratory reference range that are considered to beclinically significant by the investigator

• Current diagnosis of or receiving treatment for depression; past (within 5 years)major depressive episode according to Diagnostic and Statistical Manual of MentalDisorders-5 (DSM-5) criteria; history of suicide attempt, current suicidal risk asdetermined from history, or presence of active suicidal ideation

• History or presence of bipolar disorder, bipolar related disorders, schizophrenia,schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5criteria

• Participation in another clinical study of an investigational drug or medical devicewithin 30 days or 5 half-lives (whichever is longer) prior to check-in on Day -1

• Presence at Screening of human immunodeficiency virus (HIV) antibody, hepatitis Bsurface antigen, hepatitis C antibody, or a clinical history of these infections

• History of chronic insomnia (as defined by DSM-5 criteria)

• Has been diagnosed with sleep apnea or been identified as being at high risk forsleep apnea by standardized questionnaire (STOP-BANG)

• Any clinically relevant medical, behavioral, or psychiatric disorder that isassociated with excessive sleepiness